3 terminated. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
| Phase 2 | 1 | Terminated 1 |
Follow Solutions: new trials by email Literature Review of Solutions trials Research Report on Solutions
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) XNW5004, KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection - Carcinoma, Squamous Cell Carcinoma of Head and Neck | Phase 1 / Phase 2 | Terminated | Evopoint Biosciences Inc. | 12 | 2023-09-20 | 2026-07-23 |
| A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers Fosnetupitant 235 mg solution, Akynzeo solution - Healthy Volunteers | Phase 1 | Terminated | Helsinn Healthcare SA | 50 | 2023-06-17 | 2025-05-04 |
| Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution - Viral Infection | Phase 1 | Terminated | Emergent BioSolutions | 7 | 2016-05-27 | 2024-03-18 |
Arbovirus Infections (1) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Dengue (1) · Flaviviridae Infections (1) · Flavivirus Infections (1) · Hemorrhagic Fevers, Viral (1) · Prostatic Neoplasms (1) · RNA Virus Infections (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Uterine Cervical Neoplasms (1) · Virus Diseases (1)
Emergent BioSolutions (1) · Evopoint Biosciences Inc. (1) · Helsinn Healthcare SA (1)
China (1) · Switzerland (1) · United States (1)
Li Zhang, M.D. (1) · Milko Radicioni (1) · Timothy Babinchak, MD (1)